Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

06 Feb 2021

651.90

-1.73%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

The other regulated markets grew by 37% YoY with strong growth and market share increase in the UK, Europe and Australia. The company announced the approval to de-merge Stelis Biopharma into a standalone entity and publicly list the entity. We expect a revenue/PAT CAGR of 10%/28% over FY21E-FY23E on the...

Strides Pharma Science Ltd. has lost -56.62% in the last 6 Months

Strides Pharma Science Ltd.

04 Feb 2021

651.90

-1.73%

Slower US/Africa biz drag down earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR)'s 3QFY21 performance came in below estimates due to the COVID-related impact on the US and Africa biz. Recovery in the Other Regulated (OTR) business was led by healthy volume traction. At the strategic level, STR would de-merge its Biotech business under Stelis Biopharma and intends to list this, thereby unlocking value for shareholders. We cut our earnings estimate by 19%/7%/5% for FY21/FY22/FY23, accounting for weak Flu season related demand in the US and slower offtake of medicines related to Acute therapies in the Africa business. We roll...

Promoters unpledged 2.27% of shares in last quarter. Total pledge stands at 51.98% of promoter holdings

Strides Pharma Science Ltd.

30 Oct 2020, 12:00AM

651.90

-1.73%

2Q - COVID-led aberration hurts performance

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR)'s 2QFY21 performance came in below estimates due to COVID-related a) disruptions at its manufacturing facilities and b) softness in demand in the UK / select European countries. However, the outlook remains positive, with normalcy back in manufacturing operations. We cut our earnings estimate by 10.2%/4.9% for FY21/FY22, factoring in COVID-related disruption in 2QFY21. We value STR on a 12M forward SOTP basis EV/EBITDA of 11x for Regulated segment, 6x for Emerging Markets (EM) segment, and 7x for Institutional segment to arrive at Target Price of...

Strides Pharma Science Ltd. has lost -25.64% in the last 1 Year

Strides Pharma Science Ltd.

29 Oct 2020, 12:00AM

651.90

-1.73%

Strides Pharma

Buy: Strides Pharma Science Ltd.

Sharekhan

Q2FY2021 was a soft quarter for Strides. The results missed estimates. Revenues grew 11% YoY to Rs 793 crore while the adjusted PAT at Rs 44 crore declined by 9%. Strtides expects a marked improvement in its performance in 2HFY2021 as compared...

Strides Pharma Science Ltd. has lost -25.64% in the last 1 Year

Strides Pharma Science Ltd.

06 Aug 2020

651.90

-1.73%

Strong revival in earnings led by Other Regulated / Africa

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

We roll our price target to INR650 on a 12M forward SOTP basis (8x EV/EBITDA for the US / Other Regulated markets, 6x for Emerging Markets, and 5x for Institutional). Considering this and its increased market share in commercialized products, we expect US sales to revive and exhibit a 6% CAGR to USD270m over STR recorded the highest ever quarterly revenue of INR2.6b in the Other Regulated market, implying growth of 53% on a YoY basis in 1QFY21. We expect the business to exhibit a 23% CAGR in sales to INR12.6b over STR exhibited 17% YoY / 47% QoQ growth in the Emerging Markets business, led by an increase in primary sales in Africa. in Other Regulated and 52% sales CAGR in Emerging Markets, supported by our price target to INR650 on a 12M forward SOTP basis (8x EV/EBITDA for US / Other Regulated, 6x for Emerging Markets, and 5x for Institutional).

Strides Pharma Scien.. has an average target of 1524.50 from 2 brokers.

Strides Pharma Science Ltd.

26 May 2020

651.90

-1.73%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

We upgrade our rating to Accumulate based on 10x FY22 EPS with a target of price of Rs.485 as new launches in U.S and other regulated markets will drive growth. Revenues were down 26% yoy and down 16% qoq mainly on...

Strides Pharma Scien.. has an average target of 1524.50 from 2 brokers.

Strides Pharma Science Ltd.

17 Mar 2020

651.90

-1.73%

STRIDES PHARMA SCIENCE LIMITED

Hold: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

The U.S sales grew 62% YoY (16% QoQ) during the quarter, with the move to front end sales paying dividends. Other regulated markets saw 54% in YoY growth in revenue, led by...

Strides Pharma Science Ltd. is trading above its 50 day SMA of 642.5

Strides Pharma Science Ltd.

30 Jan 2020, 12:00AM

651.90

-1.73%

Reset strategy + product-specific opportunity drive earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Further, the company appears set to build biopharma and injectables as new levers of growth over the next 3-4 years. We expect ramp-ups to progress well on the back of new launches and increased traction in existing products. We raise our EPS estimate by 21%/12.6%/8.4% for FY20/21/22 to factor in strong traction in US generics and other regulated markets. Re-iterate led by US business (+62% YoY/16% QoQ to INR4.6b or USD66m) and other regulated markets business (+54% YoY to INR2.2b). However, emerging market sales declined 62% YoY to INR566m. Gross margin (GM) expanded 1,360bp YoY/620bp QoQ to 58.2%, led by a better product mix and partly on a low base of 3QFY19. Accordingly, EBITDA margin improved 420bp QoQ/1,200bp YoY to 24.7% Adj. PAT grew at a higher rate of ~330% (INR794m v/s our est.

Strides Pharma Science Ltd. has lost -56.62% in the last 6 Months

Strides Pharma Science Ltd.

11 Dec 2019

651.90

-1.73%

Biosimilars/Sterile Injectables - new growth levers in the making

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

11 December 2019 After delivering 31% CAGR in US generics revenue over FY17-19, STR appears well positioned to sustain this momentum led by its robust product pipeline (~40 under development/targets to file 20 ANDAs every year) and superior execution in approved products (led by no failure to supply, integrated APIs and cost leadership). The two-pronged strategy of (a) increasing penetration of the already approved products by entering new territories and (b) further building the product portfolio led to strong revenue growth of 67% YoY from other regulated markets in 1HFY20. Healthy order book, opportunities from product shortage (particularly in the UK) and new launches in the EU will provide STR with a good platform to grow business in the other regulated markets over the next 2-3 years (we forecast at least 50% revenue CAGR over the next two years). STR is building multiple levers in the form of a healthy ANDA pipeline and a specialized portfolio of injectables/bio pharma to deliver strong earnings growth over the next 3-4 years.

Strides Pharma Science Ltd. is trading below its 100 day SMA of 681.7

Strides Pharma Science Ltd.

16 Aug 2019

651.90

-1.73%

STRIDES PHARMA SCIENCE LIMITED

Sell: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

US business grew by 125%QoQ driven by healthy performance in the base portfolio with no major price erosions. Remediation work has started in response to the warning letter (WL) by USFDA on Puducherry plant (~7% of the total revenue of SS) with the management transferring production to other locations. Exit from Arrow investments at Australia got successfully completed with the proceeds reducing the debt significantly ~Rs1000cr. Regulated markets witnessed a modest growth (13%YoY) while...

Strides Pharma Science Ltd. is trading above its 50 day SMA of 642.5

Is Strides Pharma Science Ltd. worth buying?

480 Votes:

Buy 78.75%

Sell 11.88%

Hold 9.38%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf